DNA Diagnostics Market Size, Share & Trends Analysis Report By Technology (PCR-based Diagnostics, NGS DNA Diagnosis, In-Situ Hybridization Diagnostics), By Application (Cancer Genetics Tests), By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within Immediate
DLIF & XLIF Implants Market Growth & Trends
The global DLIF & XLIF implants market size is expected to reach USD 1.94 billion by 2030, registering to grow at a CAGR of 3.4% from 2024 to 2030 according to a new report by Grand View Research, Inc. Increasing prevalence of spinal cord injuries and diseases, growing adoption of minimally invasive surgical procedures, availability of technologically advanced products for spinal surgeries, and increasing obesity are augmenting the market.
Aging is one of the critical factors responsible for spine degeneration, which leads to instability and back pain. Thus, rising geriatric population worldwide is projected to increase the demand for DLIF and XLIF implants. These implants are minimally invasive procedures and are gaining popularity owing to their associated advantages such as reduction in duration of surgery and hospital stay, lower trauma and incisions, lower blood loss, reduced recovery time, and reduced damage to surrounding tissues & anatomical structures. DLIF and XLIF surgeries are, thus, considered viable options and being increasingly acknowledged by healthcare professionals.
Degenerative disc disease is a common cause of back pain and a widespread public health issue. It is among the leading causes for disabilities that affect the general wellbeing of people and ability to perform activities in day-to-day life. Spiraling demand for spinal surgeries and increasing number of people opting for treatment for back pain are likely to drive the overall market.
North America dominated the market in 2023, owing to increasing spinal injuries, large base of geriatric population, and rising research activities for development of innovative spine approaches. Moreover, Asia Pacific is expected to witness the fastest growth at a CAGR of 9.3% over the forecast period, owing to continuous improvements in infrastructure and healthcare facilities and rising healthcare expenditure. Mounting cases of trauma and growing geriatric population are leading to increased prevalence of spinal cord injuries, thereby propelling the regional market. Furthermore, flourishing medical tourism in the region is benefitting the growth of the market.
Some of the significant market players are Medtronic; NuVasive, Inc.; Globus Medical, Inc.; Stryker Corporation; DePuy Synthes Companies; Orthofix Holdings, Inc.; and Zimmer Biomet. These companies focus on new product launches, technological innovations, and regional expansion to consolidate their position in the market.
DLIF & XLIF Implants Market Report Highlights
DLIF & XLIF Implants Market Growth & Trends
The global DLIF & XLIF implants market size is expected to reach USD 1.94 billion by 2030, registering to grow at a CAGR of 3.4% from 2024 to 2030 according to a new report by Grand View Research, Inc. Increasing prevalence of spinal cord injuries and diseases, growing adoption of minimally invasive surgical procedures, availability of technologically advanced products for spinal surgeries, and increasing obesity are augmenting the market.
Aging is one of the critical factors responsible for spine degeneration, which leads to instability and back pain. Thus, rising geriatric population worldwide is projected to increase the demand for DLIF and XLIF implants. These implants are minimally invasive procedures and are gaining popularity owing to their associated advantages such as reduction in duration of surgery and hospital stay, lower trauma and incisions, lower blood loss, reduced recovery time, and reduced damage to surrounding tissues & anatomical structures. DLIF and XLIF surgeries are, thus, considered viable options and being increasingly acknowledged by healthcare professionals.
Degenerative disc disease is a common cause of back pain and a widespread public health issue. It is among the leading causes for disabilities that affect the general wellbeing of people and ability to perform activities in day-to-day life. Spiraling demand for spinal surgeries and increasing number of people opting for treatment for back pain are likely to drive the overall market.
North America dominated the market in 2023, owing to increasing spinal injuries, large base of geriatric population, and rising research activities for development of innovative spine approaches. Moreover, Asia Pacific is expected to witness the fastest growth at a CAGR of 9.3% over the forecast period, owing to continuous improvements in infrastructure and healthcare facilities and rising healthcare expenditure. Mounting cases of trauma and growing geriatric population are leading to increased prevalence of spinal cord injuries, thereby propelling the regional market. Furthermore, flourishing medical tourism in the region is benefitting the growth of the market.
Some of the significant market players are Medtronic; NuVasive, Inc.; Globus Medical, Inc.; Stryker Corporation; DePuy Synthes Companies; Orthofix Holdings, Inc.; and Zimmer Biomet. These companies focus on new product launches, technological innovations, and regional expansion to consolidate their position in the market.
DLIF & XLIF Implants Market Report Highlights
- Degenerative Disc Diseases (DDD) led the market with a dominant share of 47.6% in 2023. The increasing prevalence of DDD among the elderly population owing to age-related wear and tear, sedentary lifestyles, and genetic predisposition has primarily fueled the market.
- Hospitals have dominated the market with the largest global revenue share in 2023. Hospitals cater to patients with state-of-the-art equipment that enhances surgical precision and accuracy. This includes robotic-assisted surgery that offers accurate precision compared to traditional manual techniques.
- Scoliosis is expected to emerge substantially at the fastest CAGR over the forecast period. This condition is characterized by abnormal lateral curvature of the spine, owing to genetic predisposition, growth spurts during adolescence, and lifestyle shifts. It has become increasingly prevalent.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Application
1.2.3. Regional Scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Technology outlook
2.2.2. Application outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. DNA DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. DNA Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. DNA DIAGNOSTICS MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. DNA Diagnostics Market: Technology Movement Analysis
4.3. DNA Diagnostics Market by Technology Outlook (USD Billion)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. PCR-based Diagnostics
4.5.1. PCR-based Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.6. NGS DNA Diagnosis
4.6.1. NGS DNA Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.7. In-Situ Hybridization Diagnostics
4.7.1. In-Situ Hybridization Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.8. Microarrays-based Diagnostics
4.8.1. Microarrays-based Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.9. Other Technologies
4.9.1. In Other Technologies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
CHAPTER 5. DNA DIAGNOSTICS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. DNA Diagnostics Market: Application Movement Analysis
5.3. DNA Diagnostics Market by Application Outlook (USD Billion)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Cancer Genetics Tests
5.5.1. Cancer Genetics Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6. Infectious Diseases DNA Testing
5.6.1. Infectious Diseases DNA Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.2. HBV Diagnostic
5.6.2.1. HBV Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.3. TB Diagnostic
5.6.3.1. TB Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.4. CT/NG Diagnostic
5.6.4.1. CT/NG Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.5. HPV Diagnostic
5.6.5.1. HPV Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.6. MRSA Diagnostic
5.6.6.1. MRSA Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.7. Others
5.6.7.1. Others Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.7. Newborn Genetic Screening
5.7.1. Newborn Genetic Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.8. Preimplantation & Reproductive Diagnosis
5.8.1. Preimplantation & Reproductive Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9. Non-Infectious Diseases DNA Testing
5.9.1. Non-Infectious Diseases DNA Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9.2. Cardiovascular Diseases
5.9.2.1. Cardiovascular Diseases Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9.3. CNS & PNS Related
5.9.3.1. CNS & PNS Related Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9.4. Skeletal, Connective, Ectodermal & Dermal DNA Testing
5.9.4.1. Skeletal, Connective, Ectodermal & Dermal DNA Testing Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9.5. Lung, Kidney, Liver & GT Related
5.9.5.1. Lung, Kidney, Liver & GT Related Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9.6. Sensory Diseases
5.9.6.1. Sensory Diseases Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.10. Prenatal DNA Carrier Screening
5.10.1. Prenatal DNA Carrier Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.11. Pharmacogenomics/Drug Metabolism
5.11.1. Pharmacogenomics/Drug Metabolism Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.12. Hematology & Immunology/Identity Diagnostics & Forensics
5.12.1. Hematology & Immunology/Identity Diagnostics & Forensics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.13. Others
5.13.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
CHAPTER 6. DNA DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional Dashboard
6.2. Regional DNA Diagnostics Market movement analysis
6.3. DNA Diagnostics Market: Regional Estimates & Trend Analysis by Technology, Biomaterial & End-use
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. North America
6.5.1. North America DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5.2. U.S.
6.5.2.1. U.S. DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5.2.2. Key Country Dynamics
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Scenario
6.5.2.5. Competitive Scenario
6.5.3. Canada
6.5.3.1. Canada DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5.3.2. Key Country Dynamics
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Scenario
6.5.3.5. Competitive Scenario
6.5.4. Mexico
6.5.4.1. Canada DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5.4.2. Key Country Dynamics
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Scenario
6.5.4.5. Competitive Scenario
6.6. Europe
6.6.1. Europe DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.2. UK
6.6.2.1. UK DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.2.2. Key Country Dynamics
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Scenario
6.6.2.5. Competitive Scenario
6.6.3. Germany
6.6.3.1. Germany DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.3.2. Key Country Dynamics
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Scenario
6.6.3.5. Competitive Scenario
6.6.4. France
6.6.4.1. France DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.4.2. Key Country Dynamics
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Scenario
6.6.4.5. Competitive Scenario
6.6.5. Italy
6.6.5.1. Italy DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.5.2. Key Country Dynamics
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Scenario
6.6.5.5. Competitive Scenario
6.6.6. Spain
6.6.6.1. Spain DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.6.2. Key Country Dynamics
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Scenario
6.6.6.5. Competitive Scenario
6.6.7. Denmark
6.6.7.1. Denmark DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.7.2. Key Country Dynamics
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Scenario
6.6.7.5. Competitive Scenario
6.6.8. Norway
6.6.8.1. Norway DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.8.2. Key Country Dynamics
6.6.8.3. Regulatory Framework
6.6.8.4. Reimbursement Scenario
6.6.8.5. Competitive Scenario
6.6.9. Sweden
6.6.9.1. Sweden DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.9.2. Key Country Dynamics
6.6.9.3. Regulatory Framework
6.6.9.4. Reimbursement Scenario
6.6.9.5. Competitive Scenario
6.7. Asia Pacific
6.7.1. Asia Pacific DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.2. Japan
6.7.2.1. Japan DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.2.2. Key Country Dynamics
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Scenario
6.7.2.5. Competitive Scenario
6.7.3. China
6.7.3.1. China DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.3.2. Key Country Dynamics
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Scenario
6.7.3.5. Competitive Scenario
6.7.4. India
6.7.4.1. India DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.4.2. Key Country Dynamics
6.7.4.3. Regulatory Framework
6.7.4.4. Reimbursement Scenario
6.7.4.5. Competitive Scenario
6.7.5. South Korea
6.7.5.1. South Korea DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.5.2. Key Country Dynamics
6.7.5.3. Regulatory Framework
6.7.5.4. Reimbursement Scenario
6.7.5.5. Competitive Scenario
6.7.6. Australia
6.7.6.1. Australia DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.6.2. Key Country Dynamics
6.7.6.3. Regulatory Framework
6.7.6.4. Reimbursement Scenario
6.7.6.5. Competitive Scenario
6.7.7. Thailand
6.7.7.1. Thailand DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.7.2. Key Country Dynamics
6.7.7.3. Regulatory Framework
6.7.7.4. Reimbursement Scenario
6.7.7.5. Competitive Scenario
6.8. Latin America
6.8.1. Latin America DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.8.2. Brazil
6.8.2.1. Brazil DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.8.2.2. Key Country Dynamics
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Scenario
6.8.2.5. Competitive Scenario
6.8.3. Argentina
6.8.3.1. Argentina DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.8.3.2. Key Country Dynamics
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Scenario
6.8.3.5. Competitive Scenario
6.9. Middle East & Africa
6.9.1. Middle East & Africa DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.9.2. South Africa
6.9.2.1. South Africa DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.9.2.2. Key Country Dynamics
6.9.2.3. Regulatory Framework
6.9.2.4. Reimbursement Scenario
6.9.2.5. Competitive Scenario
6.9.3. Saudi Arabia
6.9.3.1. Saudi Arabia DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.9.3.2. Key Country Dynamics
6.9.3.3. Regulatory Framework
6.9.3.4. Reimbursement Scenario
6.9.3.5. Competitive Scenario
6.9.4. UAE
6.9.4.1. UAE DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.9.4.2. Key Country Dynamics
6.9.4.3. Regulatory Framework
6.9.4.4. Reimbursement Scenario
6.9.4.5. Competitive Scenario
6.9.5. Kuwait
6.9.5.1. Kuwait DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.9.5.2. Key Country Dynamics
6.9.5.3. Regulatory Framework
6.9.5.4. Reimbursement Scenario
6.9.5.5. Competitive Scenario
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Market Participant Categorization
7.2. Company Categorization
7.3. Strategy Mapping
7.3.1. NEW PRODUCT LAUNCH
7.3.2. PARTNERSHIPS
7.3.3. ACQUISITION
7.3.4. COLLABORATION
7.4. Key Company Market Share Analysis, 2023
7.5. Key Company Profiles
7.5.1. Abbott
7.5.1.1. Company overview
7.5.1.2. Financial performance
7.5.1.3. Technology benchmarking
7.5.1.4. Strategic initiatives
7.5.2. F. Hoffmann-La Roche Ltd.
7.5.2.1. Company overview
7.5.2.2. Financial performance
7.5.2.3. Technology benchmarking
7.5.2.4. Strategic initiatives
7.5.3. QIAGEN
7.5.3.1. Company overview
7.5.3.2. Financial performance
7.5.3.3. Technology benchmarking
7.5.3.4. Strategic initiatives
7.5.4. Bio-Rad Laboratories, Inc.
7.5.4.1. Company overview
7.5.4.2. Financial performance
7.5.4.3. Technology benchmarking
7.5.4.4. Strategic initiatives
7.5.5. Thermo Fisher Scientific, Inc.
7.5.5.1. Company overview
7.5.5.2. Financial performance
7.5.5.3. Technology benchmarking
7.5.5.4. Strategic initiatives
7.5.6. Illumina, Inc.
7.5.6.1. Company overview
7.5.6.2. Financial performance
7.5.6.3. Technology benchmarking
7.5.6.4. Strategic initiatives
7.5.7. Hologic, Inc.
7.5.7.1. Company overview
7.5.7.2. Financial performance
7.5.7.3. Technology benchmarking
7.5.7.4. Strategic initiatives
7.5.8. Agilent Technologies Inc.
7.5.8.1. Company overview
7.5.8.2. Financial performance
7.5.8.3. Technology benchmarking
7.5.8.4. Strategic initiatives
7.5.9. Siemens Healthineers AG
7.5.9.1. Company overview
7.5.9.2. Financial performance
7.5.9.3. Technology benchmarking
7.5.9.4. Strategic initiatives
7.5.10. Danaher Corporation
7.5.10.1. Company overview
7.5.10.2. Financial performance
7.5.10.3. Technology benchmarking
7.5.10.4. Strategic initiatives
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Technology
1.2.2. Application
1.2.3. Regional Scope
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Technology outlook
2.2.2. Application outlook
2.3. Regional outlook
2.4. Competitive Insights
CHAPTER 3. DNA DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. DNA Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
CHAPTER 4. DNA DIAGNOSTICS MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
4.1. Segment Dashboard
4.2. DNA Diagnostics Market: Technology Movement Analysis
4.3. DNA Diagnostics Market by Technology Outlook (USD Billion)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. PCR-based Diagnostics
4.5.1. PCR-based Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.6. NGS DNA Diagnosis
4.6.1. NGS DNA Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.7. In-Situ Hybridization Diagnostics
4.7.1. In-Situ Hybridization Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.8. Microarrays-based Diagnostics
4.8.1. Microarrays-based Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
4.9. Other Technologies
4.9.1. In Other Technologies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
CHAPTER 5. DNA DIAGNOSTICS MARKET: APPLICATION ESTIMATES & TREND ANALYSIS
5.1. Segment Dashboard
5.2. DNA Diagnostics Market: Application Movement Analysis
5.3. DNA Diagnostics Market by Application Outlook (USD Billion)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Cancer Genetics Tests
5.5.1. Cancer Genetics Tests Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6. Infectious Diseases DNA Testing
5.6.1. Infectious Diseases DNA Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.2. HBV Diagnostic
5.6.2.1. HBV Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.3. TB Diagnostic
5.6.3.1. TB Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.4. CT/NG Diagnostic
5.6.4.1. CT/NG Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.5. HPV Diagnostic
5.6.5.1. HPV Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.6. MRSA Diagnostic
5.6.6.1. MRSA Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.6.7. Others
5.6.7.1. Others Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.7. Newborn Genetic Screening
5.7.1. Newborn Genetic Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.8. Preimplantation & Reproductive Diagnosis
5.8.1. Preimplantation & Reproductive Diagnosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9. Non-Infectious Diseases DNA Testing
5.9.1. Non-Infectious Diseases DNA Testing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9.2. Cardiovascular Diseases
5.9.2.1. Cardiovascular Diseases Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9.3. CNS & PNS Related
5.9.3.1. CNS & PNS Related Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9.4. Skeletal, Connective, Ectodermal & Dermal DNA Testing
5.9.4.1. Skeletal, Connective, Ectodermal & Dermal DNA Testing Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9.5. Lung, Kidney, Liver & GT Related
5.9.5.1. Lung, Kidney, Liver & GT Related Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.9.6. Sensory Diseases
5.9.6.1. Sensory Diseases Diagnostic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.10. Prenatal DNA Carrier Screening
5.10.1. Prenatal DNA Carrier Screening Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.11. Pharmacogenomics/Drug Metabolism
5.11.1. Pharmacogenomics/Drug Metabolism Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.12. Hematology & Immunology/Identity Diagnostics & Forensics
5.12.1. Hematology & Immunology/Identity Diagnostics & Forensics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
5.13. Others
5.13.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
CHAPTER 6. DNA DIAGNOSTICS MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
6.1. Regional Dashboard
6.2. Regional DNA Diagnostics Market movement analysis
6.3. DNA Diagnostics Market: Regional Estimates & Trend Analysis by Technology, Biomaterial & End-use
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. North America
6.5.1. North America DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5.2. U.S.
6.5.2.1. U.S. DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5.2.2. Key Country Dynamics
6.5.2.3. Regulatory Framework
6.5.2.4. Reimbursement Scenario
6.5.2.5. Competitive Scenario
6.5.3. Canada
6.5.3.1. Canada DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5.3.2. Key Country Dynamics
6.5.3.3. Regulatory Framework
6.5.3.4. Reimbursement Scenario
6.5.3.5. Competitive Scenario
6.5.4. Mexico
6.5.4.1. Canada DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.5.4.2. Key Country Dynamics
6.5.4.3. Regulatory Framework
6.5.4.4. Reimbursement Scenario
6.5.4.5. Competitive Scenario
6.6. Europe
6.6.1. Europe DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.2. UK
6.6.2.1. UK DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.2.2. Key Country Dynamics
6.6.2.3. Regulatory Framework
6.6.2.4. Reimbursement Scenario
6.6.2.5. Competitive Scenario
6.6.3. Germany
6.6.3.1. Germany DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.3.2. Key Country Dynamics
6.6.3.3. Regulatory Framework
6.6.3.4. Reimbursement Scenario
6.6.3.5. Competitive Scenario
6.6.4. France
6.6.4.1. France DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.4.2. Key Country Dynamics
6.6.4.3. Regulatory Framework
6.6.4.4. Reimbursement Scenario
6.6.4.5. Competitive Scenario
6.6.5. Italy
6.6.5.1. Italy DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.5.2. Key Country Dynamics
6.6.5.3. Regulatory Framework
6.6.5.4. Reimbursement Scenario
6.6.5.5. Competitive Scenario
6.6.6. Spain
6.6.6.1. Spain DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.6.2. Key Country Dynamics
6.6.6.3. Regulatory Framework
6.6.6.4. Reimbursement Scenario
6.6.6.5. Competitive Scenario
6.6.7. Denmark
6.6.7.1. Denmark DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.7.2. Key Country Dynamics
6.6.7.3. Regulatory Framework
6.6.7.4. Reimbursement Scenario
6.6.7.5. Competitive Scenario
6.6.8. Norway
6.6.8.1. Norway DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.8.2. Key Country Dynamics
6.6.8.3. Regulatory Framework
6.6.8.4. Reimbursement Scenario
6.6.8.5. Competitive Scenario
6.6.9. Sweden
6.6.9.1. Sweden DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.6.9.2. Key Country Dynamics
6.6.9.3. Regulatory Framework
6.6.9.4. Reimbursement Scenario
6.6.9.5. Competitive Scenario
6.7. Asia Pacific
6.7.1. Asia Pacific DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.2. Japan
6.7.2.1. Japan DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.2.2. Key Country Dynamics
6.7.2.3. Regulatory Framework
6.7.2.4. Reimbursement Scenario
6.7.2.5. Competitive Scenario
6.7.3. China
6.7.3.1. China DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.3.2. Key Country Dynamics
6.7.3.3. Regulatory Framework
6.7.3.4. Reimbursement Scenario
6.7.3.5. Competitive Scenario
6.7.4. India
6.7.4.1. India DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.4.2. Key Country Dynamics
6.7.4.3. Regulatory Framework
6.7.4.4. Reimbursement Scenario
6.7.4.5. Competitive Scenario
6.7.5. South Korea
6.7.5.1. South Korea DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.5.2. Key Country Dynamics
6.7.5.3. Regulatory Framework
6.7.5.4. Reimbursement Scenario
6.7.5.5. Competitive Scenario
6.7.6. Australia
6.7.6.1. Australia DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.6.2. Key Country Dynamics
6.7.6.3. Regulatory Framework
6.7.6.4. Reimbursement Scenario
6.7.6.5. Competitive Scenario
6.7.7. Thailand
6.7.7.1. Thailand DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.7.7.2. Key Country Dynamics
6.7.7.3. Regulatory Framework
6.7.7.4. Reimbursement Scenario
6.7.7.5. Competitive Scenario
6.8. Latin America
6.8.1. Latin America DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.8.2. Brazil
6.8.2.1. Brazil DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.8.2.2. Key Country Dynamics
6.8.2.3. Regulatory Framework
6.8.2.4. Reimbursement Scenario
6.8.2.5. Competitive Scenario
6.8.3. Argentina
6.8.3.1. Argentina DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.8.3.2. Key Country Dynamics
6.8.3.3. Regulatory Framework
6.8.3.4. Reimbursement Scenario
6.8.3.5. Competitive Scenario
6.9. Middle East & Africa
6.9.1. Middle East & Africa DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.9.2. South Africa
6.9.2.1. South Africa DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.9.2.2. Key Country Dynamics
6.9.2.3. Regulatory Framework
6.9.2.4. Reimbursement Scenario
6.9.2.5. Competitive Scenario
6.9.3. Saudi Arabia
6.9.3.1. Saudi Arabia DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.9.3.2. Key Country Dynamics
6.9.3.3. Regulatory Framework
6.9.3.4. Reimbursement Scenario
6.9.3.5. Competitive Scenario
6.9.4. UAE
6.9.4.1. UAE DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.9.4.2. Key Country Dynamics
6.9.4.3. Regulatory Framework
6.9.4.4. Reimbursement Scenario
6.9.4.5. Competitive Scenario
6.9.5. Kuwait
6.9.5.1. Kuwait DNA Diagnostics Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
6.9.5.2. Key Country Dynamics
6.9.5.3. Regulatory Framework
6.9.5.4. Reimbursement Scenario
6.9.5.5. Competitive Scenario
CHAPTER 7. COMPETITIVE LANDSCAPE
7.1. Market Participant Categorization
7.2. Company Categorization
7.3. Strategy Mapping
7.3.1. NEW PRODUCT LAUNCH
7.3.2. PARTNERSHIPS
7.3.3. ACQUISITION
7.3.4. COLLABORATION
7.4. Key Company Market Share Analysis, 2023
7.5. Key Company Profiles
7.5.1. Abbott
7.5.1.1. Company overview
7.5.1.2. Financial performance
7.5.1.3. Technology benchmarking
7.5.1.4. Strategic initiatives
7.5.2. F. Hoffmann-La Roche Ltd.
7.5.2.1. Company overview
7.5.2.2. Financial performance
7.5.2.3. Technology benchmarking
7.5.2.4. Strategic initiatives
7.5.3. QIAGEN
7.5.3.1. Company overview
7.5.3.2. Financial performance
7.5.3.3. Technology benchmarking
7.5.3.4. Strategic initiatives
7.5.4. Bio-Rad Laboratories, Inc.
7.5.4.1. Company overview
7.5.4.2. Financial performance
7.5.4.3. Technology benchmarking
7.5.4.4. Strategic initiatives
7.5.5. Thermo Fisher Scientific, Inc.
7.5.5.1. Company overview
7.5.5.2. Financial performance
7.5.5.3. Technology benchmarking
7.5.5.4. Strategic initiatives
7.5.6. Illumina, Inc.
7.5.6.1. Company overview
7.5.6.2. Financial performance
7.5.6.3. Technology benchmarking
7.5.6.4. Strategic initiatives
7.5.7. Hologic, Inc.
7.5.7.1. Company overview
7.5.7.2. Financial performance
7.5.7.3. Technology benchmarking
7.5.7.4. Strategic initiatives
7.5.8. Agilent Technologies Inc.
7.5.8.1. Company overview
7.5.8.2. Financial performance
7.5.8.3. Technology benchmarking
7.5.8.4. Strategic initiatives
7.5.9. Siemens Healthineers AG
7.5.9.1. Company overview
7.5.9.2. Financial performance
7.5.9.3. Technology benchmarking
7.5.9.4. Strategic initiatives
7.5.10. Danaher Corporation
7.5.10.1. Company overview
7.5.10.2. Financial performance
7.5.10.3. Technology benchmarking
7.5.10.4. Strategic initiatives
